Navigation Links
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I
Date:10/2/2008

PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.

Neuropathic pain is a major chronic pain condition, with an estimated prevalence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

This compound originates from the work of Pharmaleads' chief scientists, Professors Bernard P. Roques and Marie-Claude Fournie-Zaluski, and is a dual inhibitor of both enzymes responsible for the rapid degradation of enkephalins, the endogenous opiates. It therefore elicits an analgesic effect wherever enkephalins are produced as a response to a painful stimulus, and maintains a high level of these natural analgesic substances by preventing their rapid degradation.

According to Thierry Bourbie, Chairman and CEO of Pharmaleads, "PL37 is Pharmaleads' first compound to enter clinical development and the first representative of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug development company. Neuropathic pain remains poorly treated and there is an urgent need to develop and bring to patients and doctors a specific oral treatment that would be really active and well tolerated. This looks very promising."

Bernard P. Roques, Vice-President and CSO of Pharmaleads explains: "The inhibition of both enzymes, responsible for the inactivation, in the body, of naturally present opiates, enhances their analgesic properties. PL37 physiological action in all areas where pain is present leads to very promising prope
'/>"/>

SOURCE Pharmaleads
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine technology :

1. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
4. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
5. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
9. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...swire/ -- New research has found that the availabi... (CT) scanner in an emergency room can significant...ve a potentially life-saving treatment. Results of...r (NSMC)-Salem Hospital in Salem, Mass., will be p...ogical Society of North America (RSNA). , , ...
(Date:12/1/2008)... A study has found that...que for imaging the breast, is not affected by eit...wo factors that limit the effectiveness of standar... will be presented today at the annual meeting of ... , , "The ability of PEM to detect cancer d...
(Date:12/1/2008)...e-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq...e of the world,s leading medical journals, results...or, experimental compound tasimelteon (VEC-162). ... "Melatonin agonist tasimelteon (VEC-162) for tran...sed controlled multicentre trials." Results are re...
(Date:12/1/2008)... TargeGen has announced that an oral,presentation...ased clinical,trial of TG101348 in myeloprolifera...008 American Society of Hematology (ASH) Meeting. ...ows:, Title: A Phase I Study of... JAK2-Selective Inhibitor, in Patients wit...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Governors Task Force Cites PAs 2436 5 Billion Water Infrastructure Need 3B Report Underscores Call for Additional Investments 28454 1Governors Task Force Cites PAs 2436 5 Billion Water Infrastructure Need 3B Report Underscores Call for Additional Investments 28454 2Governors Task Force Cites PAs 2436 5 Billion Water Infrastructure Need 3B Report Underscores Call for Additional Investments 28454 3Turning Clocks Back Increases Risk of Drowsy Driving 28449 1Turning Clocks Back Increases Risk of Drowsy Driving 28449 2Nutrition 21 to Report Preliminary First Quarter Fiscal Year 2009 Financial Results on Thursday November 13 2008 28446 1Nutrition 21 to Report Preliminary First Quarter Fiscal Year 2009 Financial Results on Thursday November 13 2008 28446 2FDA Warns of Dangers of Mexican Vanilla 28441 1
...hase 2 BPD Clinical Data Selected and Presented as...lis Aerosol-Generator Technology,Demonstrates Opti...2007 (PRIME NEWSWIRE) -- Discovery,Laboratories, I...previously completed Phase 2 clinical trial of Sur...r the prevention and,treatment of Bronchopulmonary...
...ieves Primary Endpoint Among High-Risk Infants Ver...f Medically Attended,Outpatient RSV- Related Lower...PRNewswire-FirstCall/ -- MedImmune, Inc.,today ann...rial,conducted for prevention of respiratory syncy...the investigational monoclonal antibody,(MAb) also...
Other Medicine Technology:Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 2Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 3Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 4Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 5Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 6Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 7MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7
(Date:12/1/2008)...- Media entrepreneur, television and,radio host R...ropist John,Bendheim will be honored by the Cedar...To A Cure" Gala, December 2, 2008, at the Hyatt Re... of the Board of Governors, co-chairs the,event w...olomon. The "Road To,A Cure" Gala is sponsored b...
(Date:12/1/2008)...cy,s goals, commitment and resources , ...o criticism that it has done a poor job safeguardi...g Administration released a report Monday detailin... most important changes in 2008 was the agency,s i... and local health departments to protect the food ...
(Date:12/1/2008)...wire/ -- Due to the urgent need to disseminate aut...search and clinical care, publisher Mary Ann Lie...to all archival online issues of the company,s AID... World AIDS Day. Free online access is available f....com/apc ) and AIDS Research and Human Retroviru...
(Date:12/1/2008)...irstCall/ -- Senetek PLC,(OTC Bulletin Board: SNK...opment of technologies that target the science of ...p AG, specialists in the fields of strategic,deve...h offices in Zurich,Bern and Geneva has publishe...esearch Report, available in the "Investors" secti...
Breaking Medicine News(10 mins):Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
... have found out that Methicillin-resistant Staphyl...e// who before had no established risk factors for...RSA infections, and reviewing their medical record...these infections are acquired from the community. ...
...y on child behavior had pointed out that excessive... might make the child indulge in bullying behavior...peatedly harasses and attacks other children. Bull...physical attack on others or by verbal assaults, t...
...s at Institute of Bioinformatics (Bangalore) had m...omosome// with its transcriptome and proteome sequ...uman X chromosome has a gene density less than oth...oding regions and 696 known genes. The researcher...
...was conducted to find out effective treatment for ...both knees. // The treatment tested was providing...and one third patch on the back of the affected kn...ix weeks of treatment majority of the group of peo...
Other Medicine News:
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
Medicine Products: